shutterstock_1824967073_rafapress

14 December 2023Big PharmaLiz Hockley

Acadia defends Parkinson’s drug patent against obviousness-type double patenting attack

Court rules that patent must be later-filed to be available as OTDP reference | MSN had submitted ANDA for generic version of Parkinson’s treatment Nuplazid.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Fed Circuit refuses to revive Parkinson’s disease patent

13 April 2023 Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

6 July 2018 A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

More on this story

Fed Circuit refuses to revive Parkinson’s disease patent

13 April 2023 Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

6 July 2018 A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

More on this story

Fed Circuit refuses to revive Parkinson’s disease patent

13 April 2023 Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

6 July 2018 A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

More features

The flaw that landed Sanofi a win in the rare disease space

Roche resolves cancer test dispute with Stanford affiliated startup

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory

UK firm expands in Germany with more litigation hires

Sandoz blocked by UK court from seeking Xarelto profits

An update on patenting in Ukraine, Russia and Eurasia

The rise of pro-NPE and patent sentiment in the US

UPC sees rising small molecule litigation with Pfizer in the hot seat